Cancer is one of the major deadly diseases globally. The alarming rise in the mortality rate due to this disease attracks attention towards discovering potent anticancer agents to overcome its mortality rate. The discovery of novel and effective anticancer agents from natural sources has been the main point of interest in pharmaceutical research because of attractive natural therapeutic agents with an immense chemical diversity in species of animals, plants, and microorganisms. More than 60% of contemporary anticancer drugs, in one form or another, have originated from natural sources. Plants and microbial species are chosen based on their composition, ecology, phytochemical, and ethnopharmacological properties. Plants and their derivatives have played a significant role in producing effective anticancer agents. Some plant derivatives include vincristine, vinblastine, irinotecan, topotecan, etoposide, podophyllotoxin, and paclitaxel. Based on their particular activity, a number of other plant-derived bioactive compounds are in the clinical development phase against cancer, such as gimatecan, elomotecan, etc. Additionally, the conjugation of natural compounds with anti-cancerous drugs, or some polymeric carriers particularly targeted to epitopes on the site of interest to tumors, can generate effective targeted treatment therapies. Cognizance from such pharmaceutical research studies would yield alternative drug development strategies through natural sources which could be economical, more reliable, and safe to use.

This review focuses on the crucial role of aquatic ecosystems in preserving biodiversity and the biosphere, as well as the connection between antimicrobial resistance (AMR) and these ecosystems. It provides an in-depth analysis of the link between ecological well-being and public health, helping readers understand this complex subject. Aquatic ecosystems are essential for maintaining biodiversity and ecological balance. Additionally, they act as primary reservoirs and pathways for the spread of antimicrobial resistance (AMR). These ecosystems risk antibiotic contamination through various sources, such as the release of antibiotics from animal and human waste, improper disposal of unused medications, and pharmaceutical industry waste management practices. The presence of antibiotic residues in these environments significantly speeds up the development of bacterial resistance. The global prevalence of antimicrobial resistance (AMR) is evident in freshwater bodies, tributaries, sewage waters, and wastewater treatment facilities. Antimicrobial resistance (AMR) is now a significant public health threat, compromising the effectiveness of many previously successful treatments against various pathogens. One notable and alarming aspect of antimicrobial resistance (AMR) is its rapid development, often occurring within 5–10 years after introducing antimicrobial drugs to the market. This acceleration is closely tied to bacteria’s ability to thrive and adapt in the presence of antimicrobial agents and their residues in the environment. The implications of antimicrobial resistance (AMR) include treatment failures with long-term effects and a continuous increase in healthcare costs. This review comprehensively examines the intricate relationship between aquatic habitats, antibiotics, and the global challenge of antimicrobial resistance (AMR). It emphasizes the critical role of these ecosystems in preserving ecological diversity. It raises awareness about AMR’s urgent public health issue, laying a foundation for understanding its extensive consequences.

A multi-class and multi-residue/contaminant method for the determination of veterinary drug and pesticide residues and mycotoxins in bovine meat has been developed and validated. The veterinary drug residues/contaminants included antimicrobials, anabolic hormones, lactones, β-agonists, mycotoxins, and pesticides. Isotopic labeled internal standards were included to compensate residual matrix effects. The calibrators used in the method demonstrated linearity with the R² > 0.98. The decision limit (CCα) values were in the range from 0.067 to 2103.84 μg/kg, while the range for detection capability (CCβ) was from 0.083 to 2482.13 μg/kg. The limit of detection (LOD) and limit of quantification (LOQ) were in the range from 0.059 to 291.36 μg/kg, and 0.081 to 328.13 μg/kg, respectively. The recovery of analytes ranged from 61.28% to 116.20%. The intra-day coefficient of variation (CV) was from 0.97 to 25.93% and the inter-day CV was 2.30–34.04%. The method has been used for the determination of 49 residues/contaminants in bovine meat. Application of the method in routine analysis in bovine samples, revealed in limited samples the presences of enrofloxacin, oxytetracycline and sulfadiazine at the concentration of 35.22 µg/kg, 27.35 µg/kg, and 36.20 µg/kg, respectively.